Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement [Yahoo! Finance]
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Yahoo! Finance
focused on developing novel products for the treatment of Alzheimer's disease (" Alzheimer's "), bipolar disorder (" BD "), major depressive disorder (" MDD ") and post-traumatic stress disorder (" PTSD "), today announced that it has received a notification letter (the " Compliance Notice ") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (" Nasdaq ") dated November 15, 2023, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the " Minimum Bid Price Requirement "). In order to regain compliance with the Minimum Bid Price Requirement, Alzamend's common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days. The Minimum Bid Price Requirement was met on November 13, 2023. Accordingly, in the Compliance Notice, Nasdaq stated that the matter is now closed. The Compliance Notice is unrelated to the previously disclosed notice received by Alzamend from Nasdaq on
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $42.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]Yahoo! Finance
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General HospitalPR Newswire
- Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ALZN
Analyst Actions
- 12/22/25 - Ascendiant Capital
ALZN
Sec Filings
- 12/23/25 - Form 4
- 12/9/25 - Form 10-Q
- 11/18/25 - Form 8-K
- ALZN's page on the SEC website